VJHemOnc is committed to improving our service to you

VJ Virtual | Blastic plasmacytoid dendritic cell neoplasms: current and future treatment options

VJHemOnc is committed to improving our service to you

Naveen Pemmaraju

Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, discusses novel treatments that have been developed against blastic plasmacytoid dendritic cell neoplasms (BPDCP), a rare and aggressive disease affecting skin, bone marrow and lymph nodes. Tagraxofusp, a CD123 targeted therapy has gained FDA approval for BPDCN as CD123 (encoding IL3RA) is often overexpressed in these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
15th May 2020

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter